BENADRYL ALLERGY OTC
Generic Name and Formulations:
Diphenhydramine HCl 25mg; caps; tabs; dye-free liq-filled softgels.
McNeil Consumer Healthcare
Indications for BENADRYL ALLERGY:
Symptoms of upper respiratory allergies. Rhinorrhea/sneezing due to common cold.
25–50mg every 4–6hrs; max 300mg/day.
<6yrs: individualize. 6–12yrs: 12.5–25mg every 4–6hrs; max 150mg/day.
Neonates. Premature infants. Acute asthma. Concomitant diphenhydramine products (including topicals).
Asthma and lower respiratory disorders. Glaucoma. Hyperthyroidism. Hypertension. Cardiovascular disease. GI or urinary obstruction. Sodium-restricted diet. Children. Pregnancy (Cat.B in 3rd trimester): not recommended. Nursing mothers.
Potentiates CNS depression with alcohol, other CNS depressants. Potentiates anticholinergic effects with MAOIs.
Drowsiness, dizziness, anticholinergic effects, excitability in children.
Caps—24, 48; Tabs—24, 48, 100; Dye-free softgels—24; Allergy Liq—4oz, 8oz; Dye-free Liq—4oz; Inj—contact supplier
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|